Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and six months ended June 30, 2007
Filing Date: July 26, 2007
Business Overview: Global leader in ophthalmic products, operating through two segments: Alcon United States and Alcon International. Product categories include pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended June 30, 2007 |
3 Months Ended June 30, 2006 |
6 Months Ended June 30, 2007 |
6 Months Ended June 30, 2006 |
|---|---|---|---|---|
| Sales | $1,471.5 | $1,310.8 | $2,794.2 | $2,467.9 |
| Gross Profit | $1,118.2 | $985.5 | $2,091.9 | $1,854.4 |
| Gross Margin % | 76.0% | 75.2% | 74.9% | 75.1% |
| Operating Income | $536.5 | $575.8 | $939.6 | $918.2 |
| Net Earnings | $448.4 | $465.6 | $794.6 | $761.3 |
| Diluted EPS | $1.48 | $1.50 | $2.62 | $2.45 |
| Cash from Operations (6mo) | $346.7 | $747.7 | ||
| Cash & Equivalents (End Period) | ||||
| Total Debt (Short + Long Term) | $873.0 (as of June 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 12.3% (Q2) and 13.2% (YTD) compared to the prior year. Constant currency growth was 10.0% (Q2) and 10.9% (YTD), driven by volume gains in pharmaceuticals and surgical products.
- Profitability: Net earnings decreased 3.7% in Q2 but increased 4.4% YTD. The Q2 decline was primarily due to a $121.0 million benefit in 2006 from the reduction of a patent litigation provision, which did not recur in 2007.
- Impairment Charges: The Company recognized $32.7 million in impairment losses during the first half of 2007 related to refractive product assets and inventory valuation. This reduced operating income and gross margins.
- Refractive Segment: Refractive sales declined 28.1% in Q2 and 20.5% YTD due to a Device Safety Alert issued in February 2007 regarding the LADAR6000 excimer laser, which halted specific myopia procedures.
- Shareholder Returns: The Company paid $612.8 million in dividends and repurchased $744.3 million of treasury shares in the first six months of 2007.
Guidance, Outlook, Risks, and Unusual Items
- Acquisition: On July 16, 2007, Alcon announced an intent to acquire WaveLight AG for EUR 10.00 per share (approx. 34-45% premium) to strengthen its refractive laser portfolio.
- Patent Litigation: Active litigation against generic manufacturers Teva (Vigamox) and Apotex (Patanol). FDA approval for generics is delayed until August 2008 and December 2010, respectively, pending litigation outcomes.
- Regulatory Risks: The FDA rejected a Pre-Market Approval supplement for the LADAR6000 laser in May 2007. The Company is investigating visual acuity issues and expects reduced technology fee revenue until resolved.
- Tax Contingencies: The Company is subject to IRS audits (2003-2005) and negotiations for Advance Pricing Agreements (APAs) with Switzerland and Japan. Management estimates a possible net reduction in unrecognized tax benefits exceeding $50.0 million within 12 months.
- Market Risks: Significant exposure to foreign currency fluctuations and interest rate changes on short-term floating-rate debt.
Investor Verification Checklist
- Refractive Recovery: Monitor the resolution of the LADAR6000 safety alert and the impact on refractive sales recovery.
- Generic Competition: Track the status of patent litigation against Teva and Apotex, which could impact future sales of Vigamox and Patanol.
- WaveLight Integration: Verify the closing of the WaveLight AG acquisition and its contribution to the refractive segment.
- Tax Reserves: Review updates on the IRS audit and APA negotiations, as a reduction in tax reserves could impact future earnings.
- Cash Flow Usage: Assess the sustainability of high capital return (dividends and buybacks) given the significant cash outflow of over $1.3 billion in financing activities YTD.